Rubedo Life Sciences is joining forces with multi-year strategic partnership with Beiersdorf AG to develop skin care products that address the effects of cellular aging.
The partnership between Rubedo and Beiersdorf revolves around the exploration of novel compounds derived from Rubedo’s research targeting cellular senescence.
Senescent cells accumulate with age and may contribute to age-related skin changes and pathologies. These compounds will be sourced from Rubedo’s topical dermatology program, which have senolytic and anti-inflammatory properties.
As part of the partnership, Beiersdorf will conduct in vitro and in silico studies, and will conduct rigorous assessments of the identified compounds from Rubedo.
The collaborative effort will culminate in in vivo human studies, aimed at validating the efficacy of the selected compounds in cosmetic skin care formulations. Rubedo shall be eligible to receive milestones and royalty payments.
“We are thrilled to announce our partnership with Beiersdorf, a recognized global leader in the cosmetics and skin care industry to develop new products that address skin aging,” says Marco Quarta, CEO of Rubedo Life Sciences, in a news release. “For over 140 years, Beiersdorf has been a worldwide leader in skin care with global brands like Nivea, Eucerin, and La Prairie. By combining Rubedo’s expertise in cellular senescence with Beiersdorf’s complementary expertise in skin care innovation, this partnership may revolutionize the landscape of skin care products, offering consumers new solutions that treat cellular aging for healthy and youthful-looking skin.”
“Our mission is to define the future of skincare through breakthrough innovation,” adds Beiersdorf CEO Vincent Warnery. “By partnering with Rubedo and combining cutting-edge expertise from both sides, we aim to redefine the standards in anti-age skincare.”
